000			02742nam a2200301Ia 4500
003			MX-MdCICY
005			20250625162417.0
040			_cCICY
090			_aB-18694
245	1	0	_aAntiviral anticoagulation
490	0		_vRes Pract Thromb Haemost., p.1-15, 2020
520	3		_aSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)is a novel envelope virus that causes coronavirus disease 2019 (COVID-19). Hallmarks of COVID-19 are a puzzling form of thrombophilia that has elevated D-dimer but only modest effects on other parameters of coagulopathy. This is combined with severe inflammation, often leading to acute respiratory distress and possible lethality. Coagulopathy and inflammation are nterconnected by the transmembrane receptor, tissue factor (TF), which initiates blood clotting as a cofactor for factor VIIa (FVIIa)-mediated factor Xa (FXa)generation. TF also functions from within the nascent TF/FVIIa/FXa complex to trigger profound changes via protease-activated receptors (PARs)in many cell types, including SARS-CoV-2-trophic cells. Therefore, aberrant expression of TF may be the underlying basis of COVID-19 symptoms. Evidence suggests a correlation between infection with many virus types and development of clotting-related symptoms, ranging from heart disease to bleeding, depending on the virus. Since numerous cell types express TF and can act as sites for virus replication, a model envelope virus, herpes simplex virus type 1 (HSV1), has been used to investigate the uptake of TF into the envelope. Indeed, HSV1 and other viruses harbor surface TF antigen, which retains clotting and PAR signaling function. Strikingly, envelope TF is essential for HSV1 infection in mice, and the FXa-directed oral anticoagulant apixaban had remarkable antiviral efficacy. SARS-CoV-2 replicates in TF-bearing epithelial and endothelial cells and may stimulate and integrate host cell TF, like HSV1 and other known coagulopathic viruses. Combined with this possibility, the features of COVID-19 suggest that it is a TFopathy, and the TF/FVIIa/FXa complex is a feasible therapeutic target.
650	1	4	_aCOAGULATION
650	1	4	_aCOVID-19
650	1	4	_aHERPES SIMPLEX VIRUS
650	1	4	_aINFLAMMATION
650	1	4	_aPROTEASE-ACTIVATED RECEPTOR
650	1	4	_aTISSUE FACTOR
700	1	2	_aPryzdial, Edward L. G.
700	1	2	_aLin, Bryan H.
700	1	2	_aHorwitz, Marc
700	1	2	_aSutherland, Michael R.
700	1	2	_aHorwitz, Marc
700	1	2	_aSutherland, Michael R.
856	4	0	_uhttps://drive.google.com/file/d/1_1Wt6VCwRS79r_yjQPYFpibNPQu_OIHg/view?usp=drivesdk _zPara ver el documento ingresa a Google con tu cuenta: @cicy.edu.mx
942			_2Loc _cREF1
008			250602s9999 xx |||||s2 |||| ||und|d
999			_c52840 _d52840